Home › Research › Health systems and care delivery
Demographics, comorbidities, and comedications in newly diagnosed patients with Alzheimer's disease and related dementias: Findings from United States Medicare claims data
Krista Schroeder, Ana Sofía Afonso, Huabo Wang, Sarah Grace, Adam Phipps, John Randall Sims. Journal of Alzheimer s Disease, 2024-11-01
Topic: Risk, prevention and care in population studies
The newly diagnosed ADRD and new AChEI users cohorts included 861,727 and 395,319 patients, respectively. Demographics and comedications were generally similar across the two cohorts, supporting internal validity of the study results. Circulatory system-related comorbidities and mood disorders were common in both cohorts. Differences in race, inpatient claims and long-term care claims were observed between insurance types. The study results provide a reference for describing the ADRD population in the US and emphasize the importance of evaluating new Alzheimer's disease drugs in broad patient populations with comorbidities and concomitant medication use.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Schroeder, K., Afonso, A. S., Wang, H., Grace, S., Phipps, A., & Sims, J. R. (2024). Demographics, comorbidities, and comedications in newly diagnosed patients with Alzheimer's disease and related dementias: Findings from United States Medicare claims data. Journal of Alzheimer s Disease. https://doi.org/10.3233/jad-231488
Vancouver
Schroeder K, Afonso AS, Wang H, Grace S, Phipps A, Sims JR. Demographics, comorbidities, and comedications in newly diagnosed patients with Alzheimer's disease and related dementias: Findings from United States Medicare claims data. Journal of Alzheimer s Disease. 2024. doi:10.3233/jad-231488. PMID: 39539059.
BibTeX
@article{schroeder2024-39539059,
author = {Schroeder, Krista and Afonso, Ana Sofía and Wang, Huabo and Grace, Sarah and Phipps, Adam and Sims, John Randall},
title = {{Demographics, comorbidities, and comedications in newly diagnosed patients with Alzheimer's disease and related dementias: Findings from United States Medicare claims data}},
journal = {Journal of Alzheimer s Disease},
year = {2024},
doi = {10.3233/jad-231488},
pmid = {39539059},
url = {https://doi.org/10.3233/jad-231488}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The newly diagnosed ADRD and new AChEI users cohorts included 861,727 and 395,319 patients, respectively.
- Demographics and comedications were generally similar across the two cohorts, supporting internal validity of the study results.
- Circulatory system-related comorbidities and mood disorders were common in both cohorts.
- Differences in race, inpatient claims and long-term care claims were observed between insurance types.
- The study results provide a reference for describing the ADRD population in the US and emphasize the importance of evaluating new Alzheimer's disease drugs in broad patient populations with comorbidities and concomitant medication use.
Why it matters
This study describes the characteristics, other illnesses, and medications of people newly diagnosed with Alzheimer's disease and related dementias using Medicare claims data. It does not test any treatment or prevention, but notes that new Alzheimer's drugs should be evaluated in broad patient groups with other conditions and medications.
Study details
- Study designcohort study
- Participants861,727
- Evidence strengthModerate
How this study scored 48/100
Published in a peer-reviewed journal, and it is a cohort study following people over time. Scored zero for effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of Alzheimer s Disease) |
| Journal's citation record | 2 / 4 | Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 4 / 4 | 861,727 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 1 / 6 | Cited 0.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author John Randall Sims: h-index 41 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Eli Lilly (United States): institution h-index 744 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39539059) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 48 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Health systems and care delivery
Also tagged “prevalence”
1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.